# Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

> **NCT00920153** · PHASE3 · TERMINATED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 442 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** bleomycin sulfate
- **DRUG:** ABVD regimen
- **DRUG:** carmustine
- **DRUG:** cisplatin
- **DRUG:** cytarabine
- **DRUG:** dacarbazine
- **DRUG:** dexamethasone
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** ifosfamide
- **DRUG:** melphalan
- **DRUG:** methylprednisolone
- **DRUG:** mitoguazone
- **DRUG:** vincristine sulfate
- **DRUG:** vindesine
- **DRUG:** vinorelbine tartrate
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** autologous hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00920153
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 442 (ACTUAL)
- **Why stopped:** Other new drugs
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920153, "Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00920153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*